|
Video: What is a Stock Split?
|
|
Chimerix is a biopharmaceutical company focused on developing medicines that improve and extend the lives of patients facing deadly diseases. The U.S. Food and Drug Administration (FDA) approved TEMBEXA (brincidofovir) for the treatment of smallpox as a medical countermeasure. Co.'s two clinical-stage development programs are ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma as its lead indication. DSTAT is in Phase 3 development as a potential first-line therapy in combination with standard chemotherapy for the treatment of acute myeloid leukemia. According to our Chimerix stock split history records, Chimerix has had 0 splits. | |
|
Chimerix (CMRX) has 0 splits in our Chimerix stock split history database.
Looking at the Chimerix stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Chimerix shares, starting with a $10,000 purchase of CMRX, presented on a split-history-adjusted basis factoring in the complete Chimerix stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/22/2014 |
|
End date: |
04/17/2024 |
|
Start price/share: |
$21.37 |
|
End price/share: |
$0.90 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.79% |
|
Average Annual Total Return: |
-27.16% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$421.17 |
|
Years: |
9.99 |
|
|
|
|
|